Your shopping cart is currently empty

VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $89 | - | In Stock | |
| 5 mg | $342 | - | In Stock | |
| 10 mg | $513 | - | In Stock | |
| 25 mg | $917 | - | In Stock | |
| 50 mg | $1,370 | - | In Stock | |
| 100 mg | $1,860 | - | In Stock | |
| 200 mg | $2,490 | - | In Stock |
| Description | VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG). |
| In vitro | VIP(6-28)(human, rat, porcine, bovine) acetate (10, 30, or 100 μM) reduces the increase in cAMP levels produced by stimulation with 10 μM VIP by 52, 64, or 81%, respectively. Similar results on the ability of VIP(6-28)(human, rat, porcine, bovine) acetate to block VIP-stimulated increases in cAMP levels are obtained in neuron-enriched and non-neuronal cell-enriched dissociated cultures. At any of these concentrations tested, VIP(6-28)(human, rat, porcine, bovine) acetate by itself does not alter cAMP levels. In contrast to its ability to reduce the VIP-stimulated elevation in cAMP levels by 64%, the addition of 30 μM VIP(6-28)(human, rat, porcine, bovine) acetate to the culture medium does not significantly alter cAMP levels measured after stimulation of adult ganglia with either isoproterenol or forskolin (10 μM each)[1]. |
| Molecular Weight | 2876.34 |
| Formula | C128H211N37O36S |
| Smiles | CC(O)=O.O=C(C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CC(C=C1)=CC=C1O)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CCSC)NC([C@@H](NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@@](NC([C@@H](NC([C@H](CC(N)=O)NC([C@@H](NC([C@@](NC([C@@H](N)CC2=CC=CC=C2)=O)([C@@H](C)O)[H])=O)CC(O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)([C@@H](C)O)[H])=O)=O)=O)=O)=O)CCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC(N)=O)=O)=O)=O)=O)N |
| Relative Density. | 1.31g/cm3 |
| Sequence | Phe-xiThr-Asp-Asn-Tyr-xiThr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-xiIle-Leu-Asn |
| Sequence Short | FXDNYXRLRKQMAVKKYLNSXLN |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.